Allelic loss on chromosome 22Q in epithelioid sarcomas

被引:26
作者
Quezado, MM
Middleton, LP
Bryant, B
Lane, K
Weiss, SW
Merino, MJ
机构
[1] NCI, Surg Pathol Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA
[2] Univ Michigan Hosp, Dept Pathol, Ann Arbor, MI 48109 USA
关键词
epithelioid sarcoma; NF2; PCR; loss of heterozygosity;
D O I
10.1016/S0046-8177(98)80010-5
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Epithelioid sarcomas are soft tissue tumors with an indolent, but potentially aggressive, clinical behavior. Distinction from other benign and malignant entities may be a diagnostic dilemma. In this study, we evaluate the presence of loss of heterozygosity (LOH) of chromosome 22q in tumor DNA from 13 epithelioid sarcomas, four epitheliold angiosarcomas, and two epithelioid hemangioendotheliomas, and investigate its possible role in diagnosis. LOH was detected in 6 of 10 (60%) of the informative epithelioid sarcomas. No allele loss was detected in the informative vascular tumors, three angiosarcomas, and two hemangioendotheliomas. Chromosome 22q carries the locus of a tumor suppressor gene, the neurofibromatosis 2 (NF2) gene, which has been shown to be lost or mutated in some NF2-related tumors, sporadic meningiomas, and vestibular schwannomas, as well as a few other tumors. Our data suggest that a region of chromosome 22q may be the locus of a tumor suppressor gene involved in the tumorigenesis of these neoplasms. Genetic alterations of yet unknown tumor suppressor genes in this region, or even the NF2 tumor suppressor gene, may play a role in epithelioid sarcomas tumorigenesis. The fact that LOH was only detected in epithelioid sarcomas and not in the vascular tumors studied suggests a possible role for this marker in diagnosis. HUM PATHOL 29:604-608. This is a US government work. There are no restrictions on its use.
引用
收藏
页码:604 / 608
页数:5
相关论文
共 39 条
[1]  
[Anonymous], SOFT TISSUE TUMORS
[2]   ALTERNATIVE SPLICING OF THE NF2 GENE AND ITS MUTATION ANALYSIS OF BREAST AND COLORECTAL CANCERS [J].
ARAKAWA, H ;
HAYASHI, N ;
NAGASE, H ;
OGAWA, M ;
NAKAMURA, Y .
HUMAN MOLECULAR GENETICS, 1994, 3 (04) :565-568
[3]   HIGH-FREQUENCY OF INACTIVATING MUTATIONS IN THE NEUROFIBROMATOSIS TYPE-2 GENE (NF2) IN PRIMARY MALIGNANT MESOTHELIOMAS [J].
BIANCHI, AB ;
MITSUNAGA, SI ;
CHENG, JQ ;
KLEIN, WM ;
JHANWAR, SC ;
SEIZINGER, B ;
KLEY, N ;
KLEINSZANTO, AJP ;
TESTA, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (24) :10854-10858
[4]   MUTATIONS IN TRANSCRIPT ISOFORMS OF THE NEUROFIBROMATOSIS-2 GENE IN MULTIPLE HUMAN TUMOR TYPES [J].
BIANCHI, AB ;
HARA, T ;
RAMESH, V ;
GAO, JZ ;
KLEINSZANTO, AJP ;
MORIN, F ;
MENON, AG ;
TROFATTER, JA ;
GUSELLA, JF ;
SEIZINGER, BR ;
KLEY, N .
NATURE GENETICS, 1994, 6 (02) :185-192
[5]   KERATIN IN EPITHELIOID SARCOMA - AN IMMUNOHISTOCHEMICAL STUDY [J].
CHASE, DR ;
ENZINGER, FM ;
WEISS, SW ;
LANGLOSS, JM .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1984, 8 (06) :435-441
[6]   EPITHELIOID SARCOMA - DIAGNOSIS, PROGNOSTIC INDICATORS, AND TREATMENT [J].
CHASE, DR ;
ENZINGER, FM .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1985, 9 (04) :241-263
[7]   A NEW CYTOGENETIC FINDING IN AN EPITHELIOID SARCOMA, T(822)(Q22Q11) [J].
CORDOBA, JC ;
PARHAM, DM ;
MEYER, WH ;
DOUGLASS, EC .
CANCER GENETICS AND CYTOGENETICS, 1994, 72 (02) :151-154
[8]  
DELLATRE O, 1993, NATURE, V359, P162
[9]  
ENZINGER FM, 1970, CANCER-AM CANCER SOC, V26, P1029, DOI 10.1002/1097-0142(197011)26:5<1029::AID-CNCR2820260510>3.0.CO
[10]  
2-R